ProNAi Therapeutics, Inc. and Novosom Announce Collaboration to Enable Delivery of DNAi(R)-Based Cancer Therapeutics

KALAMAZOO, Mich. and HALLE, Germany--(BUSINESS WIRE)--ProNAi Therapeutics, Inc., a biopharmaceutical company pioneering a new class of nucleic-acid drugs based on DNA interference (DNAiĀ®), today announced a collaboration with Novosom AG to enable successful delivery of DNAiĀ®-based cancer therapeutics.

Back to news